Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Guidance for 2025 EBITDA Margin: Expected between 29% to 30%. Sartorius Stedim Biotech SA (SDMHF) reported a strong start to 2025 with a 10% increase in sales revenue for Bioprocess Solutions ...

Guidance for 2025 EBITDA Margin: Expected between 29% to 30%. Sartorius Stedim Biotech SA (SDMHF) reported a strong start to 2025 with a 10% increase in sales revenue for Bioprocess Solutions, driven ...

Sartorius Stedim Biotech SA (DIM), with a market capitalization of $135.93 million, reported robust earnings for the first quarter of 2025, exceeding analyst expectations with an earnings per share ...

Sartorius Stedim Biotech SA (DIM), with a market capitalization of $135.93 million, reported robust earnings for the first quarter of 2025, exceeding analyst expectations with an earnings per ...

Sales revenue at 745 million euros, up 10.4 percent in constant currencies 1 (reported: 11.7 percent) Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, started the fiscal ...

Sartorius Stedim Biotech SA / Key word(s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST ...